More than one-third of statin patients still fail to reach healthy LDL-cholesterol levels a year and a half after initiating treatment, leaving them vulnerable to adverse CV events and thousands of dollars in medical bills, according to a report in the Journal of Managed Care & Specialty Pharmacy.
Diabetic ketoacidosis is more prevalent in the U.S. than it is in Canada, according to a joint analysis from Harvard Medical School, the Cambridge Health Alliance, City University of New York and the University of Manitoba.
Intensive therapy to keep blood pressure (BP) levels below 130/80 mmHg helped lower the risk for heart attacks, strokes and other CV complications in patients with concomitant type 2 diabetes and hypertension, researchers have found.
The FDA has expanded Praluent’s (alirocumab) regulatory approval to reflect the reduced risk of heart attack, stroke and unstable angina evidenced in 2018’s ODYSSEY OUTCOMES trial—a move announced the same day drugmaker Sanofi released its first-quarter earnings, which were lower than expected.
The popular diabetes drug metformin reversed left ventricular hypertrophy (LVH) in a randomized trial of patients with coronary artery disease but without diabetes, suggesting a potential new use for the medication.
The FDA has cleared Gelesis100 hydrogel capsules to be used as a weight management aid alongside diet and exercise in adults with body mass indexes (BMIs) ranging from 25 to 40, according to an April 14 press release from the product’s manufacturer.
The FDA’s decision to mandate labeling of added sugar content on packaged foods and beverages is estimated to prevent nearly 1 million cases of diabetes and cardiovascular disease over the next 20 years and save the U.S. $31 billion in net healthcare costs over that timeframe.
French drugmaker Sanofi announced on April 10 a plan to lower its insulin prices to $99 per month for some U.S. patients, beginning in June. The announcement came amid a series of congressional hearings about drug costs and was met with questions about why this move and other recent cost-cutting measures took so long.